2 September 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Scancell
Announces its Attendance at Upcoming
Conferences
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
is pleased to confirm that it will be presenting at, and will also
attend, several upcoming conferences and events in September,
October and November 2024. Presentations at these high-profile
conferences follow the significant recent progress that Scancell
has made in both pre-clinical and clinical development.
These include:
· ADC &
Radiopharmaceuticals Pharma & Biotech Partnering
Summit taking place in Boston,
Massachusetts, USA from 9-10 September.
Mandeep Sehmi, Head of Business
Development, will be attending the conference.
· ESMO
Congress 2024 taking place in
Barcelona, Spain from 13-17 September
Dr Nermeen Varawalla, Chief Medical
Officer, and Dr Robert Miller, Medical Director, will be attending
the conference.
·
Vaccines & Immunotherapies Online Symposium
taking place virtually on Thursday, 26
September.
Samantha Paston, Head of
Translational Research, will be presenting.
Title: Phase 2 clinical trial, a DNA
cancer vaccine, SCIB1, in patients with advanced unresectable
melanoma receiving nivolumab + ipilimumab
Time: 4.20pm BST
·
Festival of Biologics taking place in
Basel, Switzerland from 15-17 October.
Prof Lindy Durrant, Chief Executive
Officer and Chief Scientific Officer, will be
presenting.
Session Title: Therapeutic Vaccine
Development
Title: Clinical update on the DC
targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting
citrullination
Date and Time: Wednesday, 16 October
at 5.30pm CEST
· 16th Annual PEGS Europe
taking place in Barcelona, Spain and virtually
from 5-7 November.
Mireille Vankemmelbeke, Principal
Scientist, will be presenting.
Session Title: Antibody-Based Cancer
Therapies: Novel Targets
Title: Fucosyl-GM1: A Versatile
Target for SCLC Therapy
Date and Time: Tuesday, 5 November
at 5.05pm CEST
If you would like to arrange a
meeting with management, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For
further information, please contact:
|
|
|
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Professor Lindy Durrant,
CEO
|
|
|
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Emma Earl, Freddy Crossley, Will
Goode, Mark Rogers (Corporate Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint
Broker)
David Wilson/Claes Spang/Satheesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela
Gray/Lindsey Neville
|
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab®
for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab®) or enhances the potency of antibodies and their
ability to directly kill tumour cells (AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/